2,4-Dimethyl-5-(2-oxo-1,2-Dihydro-Indol-3-Ylidenemethyl)-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)Amide | 356068-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,4-Dimethyl-5-(2-oxo-1,2-Dihydro-Indol-3-Ylidenemethyl)-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)Amide
• 英文别名: N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrole-3-carboxamide
• CAS: 356068-91-2
• 化学式: C₂₂H₂₈N₄O₂
• 分子量: 380.5
• InChiKey: UJGXTMZILSGDLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  77.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-吲哚酮 、 N-(2-(二乙基氨基)乙基)-5-甲酰基-2,4-二甲基-1H-吡咯-3-甲酰胺 在 哌啶 乙醇 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以to give 422 mg (55%) of the title compound as a light yellow solid的产率得到2,4-Dimethyl-5-(2-oxo-1,2-Dihydro-Indol-3-Ylidenemethyl)-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)Amide
  参考文献：
  名称：

  Pyrrole substituted 2-indolinone protein kinase inhibitors

  摘要：

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，其调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。

  公开号：

  US07572924B2

文献信息

• Combination therapy for the treatment of cancer
  申请人：Pharmacia Corporation

  公开号：US20030216410A1

  公开（公告）日：2003-11-20

  The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

  本发明涉及使用蛋白酪氨酸激酶抑制剂与环氧合酶抑制剂，特别是环氧合酶-2选择性抑制剂，联合治疗或预防肿瘤疾病的方法。
• Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
  申请人：Sugen. Inc.

  公开号：US20030100555A1

  公开（公告）日：2003-05-29

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物可以调节蛋白激酶的活性，因此预计可用于预防和治疗蛋白激酶相关的细胞疾病，如癌症。
• Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
  申请人：Sugen, Inc

  公开号：US07320996B2

  公开（公告）日：2008-01-22

  The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors of the formula I: wherein R1, R2, R3, R4, R5, R6, and R7 are defined herein, in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

  本发明涉及使用公式I的蛋白酪氨酸激酶抑制剂的方法，用于治疗或预防肿瘤性疾病，其中R1、R2、R3、R4、R5、R6和R7在此定义，并与环氧化酶抑制剂，特别是环氧化酶-2选择性抑制剂结合使用。
• SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US20180153902A1

  公开（公告）日：2018-06-07

  The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.
• Pyrrole substituted 2-indolinone protein kinase inhibitors
  申请人：Tang Peng Cho

  公开号：US20050176802A1

  公开（公告）日：2005-08-11

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计可用于预防和治疗蛋白激酶相关的细胞疾病，如癌症。